PDE10A and Huntington disease: Overall, these findings indicate a potential role of PDE10A as neuroimaging biomarker of HD to evaluate phenoconversion at early disease stages as well as pharmacodynamic effects of disease-modification strategies during pre-symptomatic phases [145].